LEI: 213800H188ZDCWWXFA21
13 March 2023
Creo Medical Group plc
("Creo" or the "Company")
Director/PDMR and PCA Share Dealings
Further to the announcements made on 16 February 2023 and 8 March 2023, and pursuant to the recent fundraising, the Company confirms that each of the Company's Directors, Luis Collantes, a member of the Company's senior leadership team and a director of various of the Company's subsidiaries and certain PCAs, have either themselves or through parties affiliated with them acquired New Ordinary Shares at the Issue Price of 20 pence per Ordinary Share as follows:
| Director/PDMR Name | No. of New Ordinary Shares Acquired | Resultant Shareholding post transaction | % of voting rights post transaction |
| Charles Spicer | 165,119 | 308,530 | 0.09% |
| Craig Gulliford* | 1,000,000 | 1,630,466 | 0.46% |
| Richard Rees | 2,715,322 | 2,805,902 | 0.79% |
| Professor Christopher Hancock | 383,171 | 4,802,352 | 1.36% |
| David Woods | 415,255 | 440,255 | 0.13% |
| John Bradshaw | 1,265,135 | 1,371,082 | 0.39% |
| Ivonne Cantu | 125,000 | 125,000 | 0.04% |
| Luis Collantes** | 4,442,485 | 4,442,485 | 1.27% |
* These 1,000,000 shares are held by the spouse of Craig Gulliford
**Shares held via Monkey Business Consultants SL, a company owned and managed by Luis Collantes.
| Creo Medical Group plc | ||
| Richard Rees (CFO) | +44 (0)1291 606 005 | |
| | | |
| Cenkos Securities plc (Nominated Adviser, Joint Bookrunner and Joint Broker) | +44 (0)20 7397 8900 | |
| Camilla Hume/Stephen Keys (NOMAD) | | |
| Russell Kerr/Michael Johnson (Sales) | | |
| | | |
| Numis Securities Limited (Joint Bookrunner and Joint Broker) Freddie Barnfield / James Black / Duncan Monteith William Baunton (ECM) | +44 (0)20 7260 1000 | |
| | | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com | |
| Paul McManus / Sam Allen / Phillip Marriage | Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 / +44 (0)7867 984 082 | |
| | | |
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Charles Spicer | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Chairman | |
| b) | Initial notification/Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Creo Medical Group plc | |
| b) | LEI | 213800H188ZDCWWXFA21 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |
| | Identification code | GB00BZ1BLL44 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.20 | 165,119 | ||
| d) | Aggregated information | N/A single transaction | |
| | Aggregated volume | N/A single transaction | |
| | Price | N/A single transaction | |
| e) | Date of the transaction | 9 March 2023 | |
| f) | Place of the transaction | London Stock Exchange | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Kathryn Hogg (spouse of Craig Gulliford) | |
| 2 | Reason for the notification | ||
| a) | Position/status | PCA to Craig Gulliford, Chief Executive Officer | |
| b) | Initial notification/Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Creo Medical Group plc | |
| b) | LEI | 213800H188ZDCWWXFA21 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |
| | Identification code | GB00BZ1BLL44 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.20 | 1,000,000 | ||
| d) | Aggregated information | N/A single transaction | |
| | Aggregated volume | N/A single transaction | |
| | Price | N/A single transaction | |
| e) | Date of the transaction | 9 March 2023 | |
| f) | Place of the transaction | London Stock Exchange | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Richard Rees | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification/Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Creo Medical Group plc | |
| b) | LEI | 213800H188ZDCWWXFA21 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |
| | Identification code | GB00BZ1BLL44 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.20 | 2,715,322 | ||
| d) | Aggregated information | N/A single transaction | |
| | Aggregated volume | N/A single transaction | |
| | Price | N/A single transaction | |
| e) | Date of the transaction | 9 March 2023 | |
| f) | Place of the transaction | London Stock Exchange | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Professor Christopher Hancock | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Technology Officer | |
| b) | Initial notification/Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Creo Medical Group plc | |
| b) | LEI | 213800H188ZDCWWXFA21 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |
| | Identification code | GB00BZ1BLL44 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.20 | 383,171 | ||
| d) | Aggregated information | N/A single transaction | |
| | Aggregated volume | N/A single transaction | |
| | Price | N/A single transaction | |
| e) | Date of the transaction | 9 March 2023 | |
| f) | Place of the transaction | London Stock Exchange | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | David Woods | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Commercial Officer | |
| b) | Initial notification/Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Creo Medical Group plc | |
| b) | LEI | 213800H188ZDCWWXFA21 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |
| | Identification code | GB00BZ1BLL44 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.20 | 415,255 | ||
| d) | Aggregated information | N/A single transaction | |
| | Aggregated volume | N/A single transaction | |
| | Price | N/A single transaction | |
| e) | Date of the transaction | 9 March 2023 | |
| f) | Place of the transaction | London Stock Exchange | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | John Bradshaw | |
| 2 | Reason for the notification | ||
| a) | Position/status | Independent Non-Executive Director | |
| b) | Initial notification/Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Creo Medical Group plc | |
| b) | LEI | 213800H188ZDCWWXFA21 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |
| | Identification code | GB00BZ1BLL44 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.20 | 1,265,135 | ||
| d) | Aggregated information | N/A single transaction | |
| | Aggregated volume | N/A single transaction | |
| | Price | N/A single transaction | |
| e) | Date of the transaction | 9 March 2023 | |
| f) | Place of the transaction | London Stock Exchange | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Ivonne Cantu | |
| 2 | Reason for the notification | ||
| a) | Position/status | Independent Non-Executive Director | |
| b) | Initial notification/Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Creo Medical Group plc | |
| b) | LEI | 213800H188ZDCWWXFA21 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |
| | Identification code | GB00BZ1BLL44 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.20 | 125,000 | ||
| d) | Aggregated information | N/A single transaction | |
| | Aggregated volume | N/A single transaction | |
| | Price | N/A single transaction | |
| e) | Date of the transaction | 9 March 2023 | |
| f) | Place of the transaction | London Stock Exchange | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Luis Collantes | |
| 2 | Reason for the notification | ||
| a) | Position/status | PDMR | |
| b) | Initial notification/Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Creo Medical Group plc | |
| b) | LEI | 213800H188ZDCWWXFA21 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |
| | Identification code | GB00BZ1BLL44 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.20 | 4,442,485 | ||
| d) | Aggregated information | N/A single transaction | |
| | Aggregated volume | N/A single transaction | |
| | Price | N/A single transaction | |
| e) | Date of the transaction | 9 March 2023 | |
| f) | Place of the transaction | London Stock Exchange | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.